border=0
border=0
Enter any ticker symbol here to see the live quote & chart tools in action
Ticker:   
border=0 border=0 Benefits: /
  • Your filings are automatically published to your site as they are filed.
  • Investors don't have to leave your site to see filings.


  • Product Description
  • Once a report has been filed with the SEC it will be available on the website.



  • SEC Filings Section 16 Filings Only
     
    NOVADEL PHARMA INC filed this SC 13D/A on 11/19/2010.
    « Prev Page Outline Printer Friendly Entire FilingNext Page »
     

     

    CUSIP No. 66986X 10 6
    13D
    Page 12 of 15 Pages


     
    (h)
    Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;
     
    (i)
    A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or
     
    (j)
    Any action similar to any of those enumerated above.

    Item 5.  Interest in Securities of the Issuer.

    As of the date hereof and as more fully described in Item 3 above, the Reporting Persons may be deemed to be the direct and indirect beneficial owners of an aggregate of 34,650,709 shares of Common Stock and 12,462,717 currently exercisable warrant shares, over all of which securities they have shared voting and shared dispositive power.

    The 47,113,426 shares of Common Stock beneficially owned by the Reporting Persons represent 42.4% of the issued and outstanding shares of Common Stock based on 98,681,029 shares of Common Stock outstanding as of November 10, 2010 based on 98,383,458 shares of Common Stock outstanding as of November 1, 2010 as set forth by the Issuer in its Quarterly Report on Form 10-Q filed with the SEC on November 12, 2010 plus 297,571 shares issued to the Reporting Persons in the transactions described herein.  Of such 47,113,426 shares, 15,299,576, or 14.8%, are beneficially owned by Investments II; 193,233, or .2%, are beneficially owned by Advisors Fund; 15,492,809, or 15.0%, are beneficially owned by Associates II; 31,620,617, or 29.6%, are beneficially owned by each of Investments III and Associates III; and 47,113,426, or 42.4%, are beneficially owned by each of Moorin and Schreiber.

    The following sets forth certain information regarding all transactions in the Common Stock that were effected by the Reporting Persons during the past sixty days:

    Entity
    Date
    Warrants Disposed of
    Shares Acquired
    Price Per Security
    Where and How Effected
    Investments II
    9/30/2010
    1,616,162
    --
    --
    Expiration of Series B Warrants
    Investments II
    11/10/2010
    281,030
    59,953
    *
    Exercise of Warrants
    Advisors Fund
    11/10/2010
    6,763
    1,442
    *
    Exercise of Warrants
    Associates II
    11/10/2010
    287,793
    61,395
    *
    Exercise of Warrants
    Investments III
    11/10/2010
    1,107,078
    236,176
    *
    Exercise of Warrants
    Associates III
    11/10/2010
    1,107,078
    236,176
    *
    Exercise of Warrants
    Moorin
    11/10/2010
    1,394,871
    297,571
    *
    Exercise of Warrants
     

     




    border=0
    Quote & Chart Package
    Basic Stock Chart
    Basic Stock Quote
    Embedded Quote / Chart
    Embedded Full Quote / Chart
    Interactive Chart
    Intraday Chart
    Pop Up Quote
    Scrolling Ticker

    You are viewing our Quote and Chart Demo using ticker symbol NVDL
    border=0

    T 800.650.1211     F 888.329.6696     E info@stockgroup.com   © 2004 Stockgroup Media Inc.    Disclaimer